KRAS and non-small cell lung carcinoma: A phase 1 clinical trial involving monotherapy and in combination with a PD-1 inhibitor, pembrolizumab, has been completed with a cohort of 70 patients with KRAS mutant advanced or metastatic NSCLC, CRC, and PDAC (NCT03948763); however, as of now, no results from this trial have been published.